Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial.
Aponte Becerra L, Galindo Mendez B, Khan F, Lioutas V, Novak P, Mantzoros C, Ngo L, Novak V. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial. Archives Of Diabetes & Obesity 2022, 4: 403-415. PMID: 35903156, PMCID: PMC9328174.Peer-Reviewed Original ResearchContinuous glucose monitoringIntranasal insulinGlycemic variabilitySystemic insulinAdverse eventsPlacebo treatmentHypoglycemic episodesWeight gainDouble-blinded placeboSerious adverse eventsDouble-blinded trialType 2 diabetesSubcutaneous insulinDiabetes burdenPlasma glucoseCapillary glucoseInsulin sensitivitySub studyLong-term effectsSafety outcomesTrial participantsGlucose metabolismShort-term effectsInsulinDiabetesMemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial
Novak V, Mantzoros C, Novak P, McGlinchey R, Dai W, Lioutas V, Buss S, Fortier C, Khan F, Aponte Becerra L, Ngo L. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial. Journal Of Neurology 2022, 269: 4817-4835. PMID: 35482079, PMCID: PMC9046533, DOI: 10.1007/s00415-022-11119-6.Peer-Reviewed Original ResearchConceptsIntranasal insulinCerebral blood flowPlasma insulinBlood flowType 2 diabetes mellitusVerbal memorySerious adverse eventsDouble-blinded trialRandomized clinical trialsType 2 diabetesAge-related functional declineHOMA-IRAdverse eventsDiabetes mellitusPrimary outcomeWeeks treatmentHypoglycemic episodesT2DM participantsControl placeboPreliminary safetyClinical trialsFunctional declineLong-term effectsBackgroundThis studyBetter executive function